Recently, a possible mechanism has been reported that different modifications of E2F1 protein could activate different downstream genes thereby carrying out divergent functions in CRC, which was further verified by a report of a similar mechanism in prostate cancer [37, 38]. This evidence concerns the gene E2F1 and prostate carcinoma.